1An important method for seropositive seropositive rates of new coronal pneumonia in the Geneva population in Geneva, Switzerland, to assess the prevalence of SARS-CoV prevalence in the Swiss population during the recent outbreak of SARS-2anti-CoV prevalence in the Swiss population during the outbreak
The SEROCoV-POP study was a population-based study in which participants and their family members 5 years and older were randomly selected in a previous population representative survey for a series of 12 consecutive weeks of serosis surveysSerum prevalence was estimated by testing anti-SARS-CoV-2-IgG antibodies for each participant using ELISA
Between 6 April and 9 May 2020, the researchers recruited 2,766 participants from 1,339 households with a population distribution similar to that of the Canton of GenevaIn the first week, the researchers estimated the seropositive rate at 4.8% (n-341)The second week is estimated at 8.5 per cent (n-469), the third week is 10.9 per cent (n-577), the fourth week is 6.6 per cent (n-604), and the fifth week is 10.8 per cent (n-775)The seropositive risk in people aged 5-9 years (relative risk (RR: 0.32) and over 65 years of age (RR: 0.50) was significantly lower than for people aged 20-49Taking into account the time of serum conversion, the researchers estimate that for every confirmed case reported, there are 11.6 infections in the community
BRAF, MEK joint immune checkpoint inhibitors first-line treatment of advanced melanoma DOI: https://doi.org/10.1016/S0140-6736 (20) 30934-X IMspire150 study to evaluate treatment for BRAF V600 mutation-positive advanced or metastatic melanoma, researchers recently published the results
Patients with stage IIIc-IV, BRAF V600 mutation-positive melanoma who could not be removed were randomly treated with Atezolizumab or a placebo for 28 days, based on Vemurafenib and Cobimetinib treatment, for 1 cycle every 28 daysIn Cycle 1, all patients received only Vemurafenib and Cobimetinib, and atezolizumab placebo sabo sabo seision was added from cycle 2The main result of the study was a progression-free survival rate
514 patients participated in the study, including 256 in the Atezolizumab group and 258 in the control groupAt the median follow-up of 18.9 months, the progression survival rate of the Atezolizumab group was significantly longer than that of the control group (15.1 vs 10.6 months; The common treatment-related adverse events in the Atezolizumab group and control group were: elevated blood creatinine phosphokinase, diarrhea, rash, joint pain, fever, elevated alanine amino transferase, and elevated lipaseThirteen percent of patients in the Atezolizumab group and 16 percent of the control patients stopped all treatment saue due to adverse reactions
3) Recombinant adenovirus new coronary pneumonia vaccine Phase I clinical success DOI: https://doi.org/10.1016/S0140-6736 (20) 31208-3 New Coronary Pneumonia Vaccine is currently the most critical medical resources, recently researchers assessed the safety, resistance and immunology of the recombinant adenovirus 5 (AD5) COVID-19 vaccine
The study was conducted in Wuhan for phase I trial of increasing dose of vaccine Healthy adults between the ages of 18 and 60 were randomly given 5 x 1010, 1 x 1011, or 1.5 x 1011 viral particle dose strains The main result of the study was adverse events 7 days after vaccination Safety was assessed within 28 days of vaccination, and ELISA was used to determine specific antibodies, as well as neutralizing antibody responses caused by vaccination
Between 16-27 March 2020, 108 volunteers participated in the study, with 51 per cent men and an average age of 36.3 years, of whom 36 were in the low-dose group, 36 in the medium dose group and 36 in the high-dose group Thirty participants in the low-dose group (83%) reported adverse events in the first 7 days after vaccination, compared with 83% in the medium and high-dose groups and 75% of the high-dose groups The most common adverse events at the injection site were pain, with 54% of patients reporting pain, and the most common systemic adverse events were fever (46%), fatigue (44%), headache (39%) and muscle pain (17%) Adverse events were mild in all dose groups and no serious adverse events occurred 28 days after injection ELISA antibody and neutralizing antibody testing found a significant increase in antibody content 14 days after vaccination, peaking at 28 days and peaking in specific T-cell response 14 days after vaccination
Source: MedSci Original
